Controversies in the modern treatment of the advanced overian cancer;Kontroverze v moderní léčbě pokročilého ovariálního karcinomu

Klinicka Onkologie

Volumn 15, Issue 4, 2002, Pages 136-141

  Tesarik, Z ^a  

^a GYNEKOLOG   (Czech Republic)

Author keywords

Chemotherapy; Dose dense chemotherapy; Interval debulking surgery; Neoadjuvant chemotherapy; Ovarian cancer; Relapsed ovarian cancer; Taxol

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; SECOND LOOK SURGERY;

EID: 0036032494     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Pecorelli S. et al.: Ovarian cancer: Best timing and applications of debulking surgery Educational Book of the 25th ESMO Congress, Annals of Oncology, Vol 11, 2000, Supplement 3, pp 141-143
2. Rosenthal A. et al.: Ovarian Cancer Screening. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 315-325
3. Fishman D.A.: The present and future of biomarkers for the early detection of epithelial ovarian carcinoma. CME Journal of Gynecologic Oncology, Vol 4, No 1, March 1999, 33-36
4. Rob L. et al.: Zhoubné Nádory Rodidel, Moderní Gynekologie a Porodnictví 9/2000 č. 4, str. 679-705
5. Trimbos J.B.: Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 2000, 10, Supplement 1, 8-11
6. Boente M.P. et al.: The Role of Surgery in the Management of Ovarian Cancer: Primary and Interval Cytoreductive Surgery. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 326-334
7. Friedlander M.L.: Prognostic factors in ovarian cancer. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 305-314
8. Pickel H.: Prognostic factors in ovarian cancer. CME Journal of Gynecologic Oncology, Vol 4, No 1, March 1999, 8-12
9. Margina J.F.: Surgery as a prognostic factor in epithelial ovarian cancer. CME Journal of Gynecologic Oncology, Vol 4, No 1, March 1999, 41-46
10. Calvert A.H. et al.: Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor supresor gene. Seminars in Oncology, Vol 26, No 1, Suppl 2 (February), 1999, pp 90-94
11. McGuire W.P. et al.: Chemotherapy of advanced ovarian cancer. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 340-348
12. Ozols R.F.: Paclitaxel (taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 3-7
13. Vermorken J.B.: Optimal treatment for ovarian cancer: Taxoids and beyond. Educational Book of the 25th ESMO Congress, Annals of Oncology, Vol 11, 2000, Supplement 3, pp 131-138
14. Thigpen J.T.: Chemotherapy for advanced ovarian cancer: Overview of randomized trials. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 11-16
15. Ozols R.F.: Chemotherapy for ovarian cancer. Seminars in Oncology, Vol 26, No 6, Suppl 18 (December), 1999, pp 34-40
16. Piccart M.J. et al.: A new standard of care for treatment of ovarian cancer. European Journal of Cancer 36 (2000) 10-12
17. Ozols R.F.: Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 10, Supplement 1, 33-37
18. McGuire W.P. et al.: The Gynecologic Oncology Group experience in ovarian cancer. Annals of Oncology 10, (Suppl 1) S29-S34, 1999
19. du Bois A. et al.: First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - A new standard of care. Annals of Oncology 10, (Suppl 1) S35-S41, 1999
20. Berek J.S. et al.: Advanced epithelial ovarian cancer: 1998 Consensus statement. Annals of Oncology 10, (Suppl 1) S87-S92, 1999
21. Kaye S.B.: Intravenous chemotherapy for ovarian cancer - The state of art? Int J Gynecol Cancer 10, Supplement 1, 19-25
22. th ESMO Congress, Annals of Oncology, Vol 11, 2000, Supplement 3, pp 145-148
23. Bertelsen K. et al.: How long should first-line chemotherapy continue? Annals of Oncology 10, (Suppl 1) S17-S20, 1999
24. Hill M. et al.: Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Seminars in Oncology, Vol 24, No 1, Suppl 2 (February), 1997, pp S2-34 - S2-37
25. Kristensen G.B. et al.: Patients with carboplatin, paclitaxel, and epirubicin combination as first-Line chemotherapy in ovarian cancer. Seminars in Oncology, Vol 26, No 1, Suppl 2 (February) 1999, p 96
26. Trimble E.L.: Innovative therapies for advanced ovarian cancer. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 24-30
27. Nardi M. et al.: Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. Proc ASCO 1999, abstr. 1472
28. Vermorken J.B. et al.: The role of anthracyclines in epithelial ovarian cancer. Annals of Oncology 10, (Suppl 1) S43-S50, 1999
29. Tesařík Z.: Výsledky léčby pokročilého karcinomu ovaria u pacientek gynekologického oddělení Masarykova onkologického ústavu v Brně. Zkušenosti s Taxolem z Let 1994-1998. Praktická Gynekologie 6/98, s 5-18
30. Kuhn J.G.: Pharmacology and pharmacokinetics of paclitaxel. The Annals of Pharmacotherapy, 1994 May, Volume 28, S 15
31. Vermorken J.B.: The role of intraperitoneal chemotherapy in epitelial ovarian cancer. Int J Gynecol Cancer 10, Supplement 1, 26-32
32. Markman M.: Intraperitoneal therapy of ovarian cancer. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 356-360
33. Markman M. et al.: Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer? Oncology, Vol 15, No 1 (Jan 2001), pp 93-105
34. Ozols R.F. et al.: Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Annals of Oncology 10, (Suppl 1) S59-S64, 1999
35. McGuire W.P.: High-dose chemotherapeutic approaches to ovarian cancer management. Seminars in Oncology, Vol 27, No 3, Suppl 7(June), 2000, pp 41-46
36. Benedetti-Panici P.: Intraperitoneal paclitaxel in ovarian cancer patients with small or microscopic residual disease. Proc ASCO 2000, abstr. 1525
37. Cure H. et al.: Randomized Phase II Study of Periferal Blood Progenitor Cells Mobilization in Patients with Advanced Ovarian Cancer Treated with High-Dose Consolidation Chemotherapy: Comparison of Filgrastim Used Alone or in Combination with Cyclophosphamide. Proc ASCO 2000, abstr. 1560
38. Russell J.S. et al.: Multiple Cycles of High-Dose Chemotherapy for Ovarian Cancer. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 349-355
39. Sapunar F. et al.: Prognostic and predictive factors in high-dose chemotherapy for epithelial ovarian cancer. CME Journal of Gynecologic Oncology Vol 4, No 2, September 1999, pp 272-276
40. Ledermann J.A.: High-dose chemotherapy with peripheral blood stem cell transplantation in ovarian cancer. Int J Gynecol Cancer 10, Supplement 1, 53-56
41. Klener P.: Protinádorová Chemoterapie. Galén 1996, str. 141-142
42. Norton L.: Kinetic concept in the systemic drug therapy of breast cancer. Seminars in Oncology, Vol 26, No 1, Suppl 2 (February), 1999, pp 11-20
43. Markman M.: Weekly paclitaxel in the management of ovarian cancer. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 37-40
44. Fennelly D.: Weekly paclitaxel therapy: Current status and future directions in advanced ovarian cancer. Seminars in Oncology, Vol 26, No 1, Suppl 2 (February) 1999, p 97
45. Choy H. et al.: Taxanes and Radiation Therapy in Solid Tumours. Klasterski: Taxanes in the Treatment of Lung Cancer, pp 181-194
46. Hajdúch M. et al.: Monoklonární Protilátky v Onkologii. Mediforum 2000
47. Epenetos A. A. et al.: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10, Supplement 1, 44-46
48. Nicholson S. et al.: A randomised III trial of adjuvant intraperitoneal radioimmunotherapy in ovarian cancer. Proc ASCO 2000, abstr. 1514
49. Epenetos A.A. et al.: Safety of radioimmunotherapy in international ovarian cancer study. Proc ASCO 2000, abstr. 1533
50. Ozols F.R.: Management of advanced ovarian cancer consensus summary. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 47-49
51. Chi D.S.: Laparoscopy in gynecologic malignancies. Oncology June 1999, pp 773-796
52. Pignata S. et al.: Topotecan vs nihil following response to carboplatin + paclitaxel in advanced ovarian cancer. Early data on compliance and toxicity of topotecan from the multicenter Italian trials in ovarian cancer. Proc ASCO 2000, abstr. 1619
53. Alberts D.S. et al.: Altretamine consolidation for patients with stage III epithelial ovarian cancer in clinical complete remission: A southwest oncology group trial. Proc ASCO 2000, abstr. 1520
54. Rohl J.T.: Experience with tamoxifen use in ovarian cancer in the clinical practice setting. Proc ASCO 2000, abstr. 1623A
55. Hall G. et al.: Maintenance treatment with interferon for advanced ovarian cancer. Proc ASCO 2000, abstr. 1529
56. Lanciano R. et al.: Update on the role of radiotherapy in ovarian cancer. Seminars in Oncology, Vol 25, No 3 (June), 1998, pp 361-371
57. Rustin G.J.S. et al.: Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology 10, (Suppl 1) S21-S27, 1999
58. Napier M.P. et al.: CA 125 as prognostic factor. CME Journal of Gynecologic Oncology, Vol 4, No 1, March 1999, 24-29
59. Markman M.: High-risk and low risk patients based on prognostic factors: Definition of hihg-risk and low-risk in terms of management. CME Journal of Gynecologic Oncology 259-261
60. Junor E.: The impact of specialist training for surgery in ovarian cancer. Int J Gynecol Cancer 10, Supplement 1, 16-18
61. Talač R. et al.: Hodnocení lékové rezistence in vitro a její klinické implikace. Klinická Onkologie, Zvláštní číslo 2/2000, s 2-9
62. Berek J.S. et al.: Surgery during chemotherapy and at relapse of ovarian cancer. Annals of Oncology 10, (Suppl 1) S3-S7, 1999
63. Ludková A. et al.: Střední hodnoty citlivosti na jednotlivá cytostatika u nádorů různého histogenetického původu. Klinická Onkologie 13, 2000, zvláštní číslo 2, s. 33-36
64. Cwiertka K. et al.: Chemoterapie ovariálního karcinomu s ohledem na stanovení in vitro chemosensitivity - vybrané kasuistiky. Klinická Onkologie 13, 2000, zvláštní číslo 2, s. 58-61
65. Vergote I.B. et al.: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 31-36
66. Pecorelli S. et al.: Surgical versus chemical upfront debulking in advanced ovarian cancer. Int J Gynecol Cancer 10, Supplement 1, 12-15
67. Eisenhauer E.A. et al.: Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner? Annals of Oncology 10 (Suppl. 1), s9-s15, 1999
68. Rose P.G.: Chemotherapy for Recurrent Ovarian Cancer: Recent Approaches and Future Directions. Bristol-Myers Squibb Oncology Medical Services, May 1999
69. Ozols R.F.: Comparison of Taxol (Paclitaxel) Injection, Hycamtin (Topotecan), and Doxil (Liposomal Doxorubicin) in Recurrent Ovarian Cancer. Bristol-Myers Squibb Oncology Medical Services, September 2000
70. Fennelly D. et al.: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. Journal of Clinical Oncology, Vol 15, No 1 (January), 1997, pp 187-192
71. Abu-Rustum N.R. et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Seminars in Oncology, vol 24, No 5, Suppl 15 (October) 1997, pp S 15-62 - S 15-67
72. Rose P.G.: Surgery for recurrent ovarian cancer. Seminars in Oncology, Vol 27, No 3, Suppl 7 (June), 2000, pp 17-23
73. Novotvary 1996 ČR. ÚZIS ČR 1999